Lanean...
Treatment of walking impairment in multiple sclerosis with dalfampridine
Potassium channel blockade has long been considered a potential therapeutic strategy for treatment of multiple sclerosis (MS) based on the pathophysiology of demyelinated axons. Dalfampridine, which is also known as fampridine or 4-aminopyridine (4-AP), is the potassium channel blocker that has been...
Gorde:
Egile nagusia: | |
---|---|
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
SAGE Publishing
2011-03-01
|
Saila: | Therapeutic Advances in Neurological Disorders |
Sarrera elektronikoa: | https://doi.org/10.1177/1756285611403960 |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|